Bevacizumab treatment for human glioblastoma. Can it induce cognitive impairment?

Recent results from 2 double-blind, placebo-controlled phase III trials (RTOG 0825) and (AVAglio) for first-line treatment of glioblastoma patients with the VEGF antibody bevacizumab, showed similar results, related to overall and progression-free survival. The RTOG 0825 trial indicated, opposed to...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Fathpour, Pakzad, Obad, Nina, Espedal, Heidi, Stieber, Daniel, Keunen, Olivier, Sakariassen, Per Ø., Niclou, Simone P., Bjerkvig, Rolf
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2014
Teme:
Letters to the Editor
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3984560/
https://ncbi.nlm.nih.gov/pubmed/24733853
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou013
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items